CoChat

Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor

Open access
Regmi, Ajit, Aihara, Eitaro, Christe, Michael E., Varga, Gabor, Beyer, Thomas P., Ruan, Xiaoping, Beebe, Emily, O’Farrell, Libbey S., Bellinger, Melissa A., Austin, Aaron K., Lin, Yanzhu, Hu, Haitao, Konkol, Debra L., Wojnicki, Samantha, Holland, Adrienne K., Friedrich, Jessica L., Brown, Robert A., Estelle, Amanda S., Badger, Hannah S., Gaidosh, Gabriel S., Kooijman, Sander, Rensen, Patrick C.N., Coskun, Tamer, Thomas, Melissa K., Roell, William · 2024 · Cell Metabolism
Cited by 130

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor (GIPR/GLP-1R) agonist, has, in clinical trials, demonstrated greater reductions in glucose, body weight, and triglyceride levels compared with selective GLP-1R agonists in people with type 2 diabetes (T2D). However, cellular mechanisms by which GIPR agonism may contribute to these improved efficacy outcomes have not been fully defined. Using human adipocyte and mouse models, we investigated how long-acting GIPR agonists regulate fasted and fed adipocyte functions. In functional assays, GIPR agonism enhanced insulin signaling, augmented glucose uptake, and increased the conversion of glucose to glycerol in a cooperative manner with insulin; however, in the absence of insulin, GIPR agonists increased lipolysis. In diet-induced obese mice treated with a long-acting GIPR agonist, circulating triglyceride levels were reduced during oral lipid challenge, and lipoprotein-derived fatty acid uptake into adipose tissue was increased. Our findings support a model for long-acting GIPR agonists to modulate both fasted and fed adipose tissue function differentially by cooperating with insulin to augment glucose and lipid clearance in the fed state while enhancing lipid release when insulin levels are reduced in the fasted state.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2024.05.010

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 23

  1. Wilson, 2020, The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes, Diabetes Obes. Metab., 22, 2451, 10.1111/dom.14174 · DOI · Paper page
  2. Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J. Clin. Endocrinol. Metab., 76, 912
  3. Hansen, 2021, Whole-brain activation signatures of weight-lowering drugs, Mol. Metab., 47, 10.1016/j.molmet.2021.101171 · DOI · Paper page
  4. Rudovich, 2007, GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women, Regul. Pept., 142, 138, 10.1016/j.regpep.2007.02.006 · DOI
  5. Campbell, 2022, GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue, Diabetes, 71, 1115, 10.2337/db21-1166 · DOI · Paper page
  6. Lynggaard, 2020, GIP(3-30)NH2 - a tool for the study of GIP physiology, Curr. Opin. Pharmacol., 55, 31, 10.1016/j.coph.2020.08.011 · DOI
  7. Deacon, 2000, Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide, J. Clin. Endocrinol. Metab., 85, 3575
  8. Kuzio, 1974, Radioimmunoassay for gastric inhibitory polypeptide, Gastroenterology, 66, 357, 10.1016/S0016-5085(74)80134-4 · DOI · Paper page
  9. Eissing, 2013, De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health, Nat. Commun., 4, 1528, 10.1038/ncomms2537 · DOI · Paper page
  10. Allister, 2015, In vivo 2H2O administration reveals impaired triglyceride storage in adipose tissue of insulin-resistant humans, J. Lipid Res., 56, 435, 10.1194/jlr.M052860 · DOI · Paper page
  11. Rotondo, 2017, Glycerol is synthesized and secreted by adipocytes to dispose of excess glucose, via glycerogenesis and increased acyl-glycerol turnover, Sci. Rep., 7, 8983, 10.1038/s41598-017-09450-4 · DOI
  12. Nye, 2008, Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat, J. Biol. Chem., 283, 27565, 10.1074/jbc.M804393200 · DOI · Paper page
  13. Rasouli, 2007, Ectopic fat accumulation and metabolic syndrome, Diabetes Obes. Metab., 9, 1, 10.1111/j.1463-1326.2006.00590.x · DOI · Paper page
  14. Tan, 2008, Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese, Biochem. Soc. Trans., 36, 935, 10.1042/BST0360935 · DOI · Paper page
  15. Merkel, 2002, Lipoprotein lipase: genetics, lipid uptake, and regulation, J. Lipid Res., 43, 1997, 10.1194/jlr.R200015-JLR200 · DOI · Paper page
  16. Kim, 2010, GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene, J. Lipid Res., 51, 3145, 10.1194/jlr.M006841 · DOI · Paper page
  17. Christensen, 2015, Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes, Diabetes, 64, 72, 10.2337/db14-0440 · DOI · Paper page
  18. Frayn, 1998, Non-esterified fatty acid metabolism and postprandial lipaemia, Atherosclerosis, 141, S41, 10.1016/S0021-9150(98)00216-0 · DOI
  19. Joo, 2017, Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice, Diabetes, 66, 868, 10.2337/db16-0758 · DOI · Paper page
  20. Carswell, 2012, Culture of isolated human adipocytes and isolated adipose tissue, Methods Mol. Biol., 806, 203, 10.1007/978-1-61779-367-7_14 · DOI
  21. Basu, 2011, Determination of lipoprotein lipase activity using a novel fluorescent lipase assay, J. Lipid Res., 52, 826, 10.1194/jlr.D010744 · DOI · Paper page
  22. Bolstad, 2003, A comparison of normalization methods for high density oligonucleotide array data based on bias and variance, Bioinformatics, 19, 185, 10.1093/bioinformatics/19.2.185 · DOI · Paper page
  23. Rensen, 1997, Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo, J. Lipid Res., 38, 1070, 10.1016/S0022-2275(20)37190-X · DOI · Paper page

Cited by

See all 130

Metadata

Authors
Regmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., Lin, Y., Hu, H., Konkol, D. L., Wojnicki, S., Holland, A. K., Friedrich, J. L., Brown, R. A., Estelle, A. S., Badger, H. S., Gaidosh, G. S., Kooijman, S., Rensen, P. C. N., Coskun, T., Thomas, M. K., & Roell, W.
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2024-07
Volume
36
Issue
7
Pages
1534-1549.e7
ISSN
1550-4131 (ISSN-L)
OpenAlex
W4399671023
Cited by
130
References
34
FWCI
30.75
Type
journal article
Language
en
Update notices
erratum (2024-08-06)
Open access
hybrid
Licence
Funders
  • Leids Universitair Medisch Centrum
  • Eli Lilly and Company (CVON 2017-20)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. https://app.cochat.ai/papers/10.1016/j.cmet.2024.05.010
The paper
Regmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., Lin, Y., Hu, H., Konkol, D. L., Wojnicki, S., Holland, A. K., Friedrich, J. L., Brown, R. A., Estelle, A. S., Badger, H. S., . . . Roell, W. (2024). Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metabolism. https://doi.org/10.1016/j.cmet.2024.05.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.